Post J B, Frishman W H
Department of Medicine, Albert Einstein College of Medicine/Montefiore-Medical Center, Bronx, New York, USA.
J Clin Pharmacol. 1998 Jan;38(1):2-13. doi: 10.1002/j.1552-4604.1998.tb04369.x.
Fenoldopam is a selective dopamine agonist that is being considered for the parenteral treatment of systemic hypertension. In both an oral and parenteral form, the drug causes peripheral vasodilation by stimulating dopamine-1 adrenergic receptors. Its pharmaco-dynamics are reviewed in this article, along with the clinical experiences in patients with hypertensive urgencies and emergencies. Intravenous fenoldopam may provide advantages over sodium nitroprusside because it can induce both a diuresis and natriuresis, is not light sensitive, and is not associated with cyanide toxicity. There is no evidence for rebound hypertension after discontinuation of fenoldopam influsion.
非诺多泮是一种选择性多巴胺激动剂，正被考虑用于全身性高血压的胃肠外治疗。无论口服还是胃肠外给药，该药物都通过刺激多巴胺-1肾上腺素能受体引起外周血管舒张。本文对其药效学以及高血压急症和紧急情况患者的临床经验进行了综述。静脉注射非诺多泮可能比硝普钠更具优势，因为它可引起利尿和利钠作用，不具有光敏感性，且不伴有氰化物毒性。没有证据表明停止输注非诺多泮后会出现反跳性高血压。
